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Background:  Fungal  peri-prosthetic  joint  infections  (PJI) are  rare complication  following  total  knee  arthro-
plasty (TKA).  There  exists  no  established  guidelines  in the  treatment  of these  infections  and  controversies
are  focused  on the usefulness  of antifungal-loaded  cement  spacers,  the  duration  of  systemic  antifungal
treatment  and the  ideal  interval  between  implant  removal  and  reimplantation.  Therefore  we ask  if:  (1)
adding  antifungal  in  cement  space  is  a viable  solution  to manage  fungal  PJI;  (2)  there  is no adverse  effect
adding  antifungal  medication  in  cement?
Hypothesis:  We  hypothesized  that  fungal  PJI following  TKA could  be managed  successfully  by 2-stage
reimplantation  strategy  using  antifungal-loaded  cement  spacer.
Patients  and  methods:  Five  cases  of  fungal  PJI following  total  knee  arthroplasty  were treated  in  our  insti-
tution  between  2007  and  2013  using  a 2-stage  reimplantation  strategy.  The  median  elapsed  time  from
primary  arthroplasty  to the  diagnosis  of infection  was  7.4  months  (range,  5–10  months).  The  infection
was  caused  by Candida  species  in  4 cases  and  Pichia  anomala  in  1 case.  Antibiotic-  and  antifungal-loaded
articulating  cement  spacer  was  implanted  during  the  interval  between  stages.  Systemic  antifungal  agents
were  administered  for at least  6 weeks  after  removal  of  prosthesis  in  all cases.  The  mean  interval  between
removal  and  reimplantation  was  6  months  (range,  3–9 months).
Results:  At  a mean  follow-up  of  41.6  months  (range,  24–65  months)  after  reimplantation,  no patient  had
recurrent  infection  or  revision  due to any  other  reasons.  The  mean  global  IKS  score  improved  from  58.4
(range, 37–96  points)  preoperatively  to 152.4  (range,  136–169  points)  at ﬁnal  follow-up.  The  average
range  of  motion  of the  knee  for ﬂexion  improved  from  63◦ (range,  10–110◦)  preoperatively  to  98◦ (range,
80–120◦)  at  ﬁnal  follow-up.
Conclusions:  Fungal  PJI  following  TKA  can  be  successfully  treated  by a staged  reimplantation  strategy.
Antibiotic-  and antifungal-loaded  cement  spacer  implanted  during  interval  period  between  stages  may
be an effective  adjunct  to  therapy.  Effective  antifungal  therapy  is  crucial  to a  successful  result  without
adverse  effect.
Level of evidence:  IV: retrospective  or historical  series.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Prosthetic joint infection (PJI) is the most debilitating and
xpensive complication following arthroplasty. A nationwide study
erformed in the USA showed an infection burden of 1.21% for total
nee arthroplasty (TKA) [1]. Fungal PJI following TKA is uncommon,
ith a current incidence not precisely known, but estimated to con-
titute about 1% of all PJI [2]. A recent evaluation of the English
∗ Corresponding author. Tel.: +86 21 24058101; fax: +86 21 24058101.
E-mail address: xlzhang40@gmail.com (X.-L. Zhang).
http://dx.doi.org/10.1016/j.otsr.2014.11.014
877-0568/© 2015 Elsevier Masson SAS. All rights reserved.literature for the past 30 years revealed only 94 cases of fungal
infection of a knee arthroplasty [3].
So far, there exists no established guidelines in the treatment of
fungal peri-prosthetic joint infections. Several different treatment
methods, including antifungal drugs, debridement with retained
prosthesis, resection arthroplasty, and two-stage exchange arthro-
plasty have been reported, with variable outcomes [4–8]. Although
a two-stage exchange arthroplasty was preferred by most sur-
geons [3], controversies still exist with regard to the ideal interval
between implant removal and reimplantation, the usefulness of
antifungal-loaded cement spacers and the duration of systemic
antifungal treatment. Therefore, we introduced a 2-stage strategy
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nd we treated 5 cases of fungal PJI following total knee arthro-
lasty. The aims of this study were to assess:
if adding antifungal in cement space is a viable solution to manage
fungal PJI;
the rate of healing after a speciﬁc 2-stage protocol.
We  hypothesized that fungal PJI following TKA could be man-
ged successfully by removal of all the infected components,
mplantation of antibiotic- and antifungal-loaded cement spacers
uring interval stage, appropriate antifungal treatment for at least
ix weeks and a two-stage reimplantation.
. Patients and methods
.1. Study population
After Institutional Review Board approval, we retrospectively
eviewed our institutional joint arthroplasty database to identify
atients who were diagnosed with a knee fungal peri-prosthetic
oint infection at our institution. We  deﬁned fungal PJI as “deﬁ-
ite” if 2 cultures of either a joint aspiration specimen or a surgical
pecimen yielded deﬁnitive positive result, in conjunction with
n appropriate clinical syndrome [9]. Growth on the chromogenic
edium Candida (CHROMagar) and the automated VITEX-60 sys-
em (bioMerieux) were used for fungal identiﬁcation. Treatment
ailure was deﬁned as the occurrence of any of the following con-
itions at any time after the initial surgical procedure:
peri-prosthetic joint infections attributable to the presence of the
original microorganism (relapse of infection) or a different strain
(reinfection);
development of a sinus tract;
death related to the peri-prosthetic joint infection.
Between January 2007 and November 2013, a total of 95 patients
ith PJI following TKA were treated at our institution. Among these,
 cases in 5 patients (2 male, 3 female) mean aged 67 years (56 to
2) were identiﬁed as having fungal PJI following TKA (Table 1).
he diagnosis indicated for primary arthroplasty was osteoarthri-
is and the initial TKA was cemented in all 5 patients. The median
uration of time from prosthesis implantation to the diagnosis of PJI
as 7.4 months (range, 5–10). No patient had prior hospitalization
r prolonged antibiotic use. One patient (case No. 1) had diabetes
ellitus and leucopenia, 1 patient (case No. 3) had diabetes melli-
us, the other 3 patients had no identiﬁable risk factors for fungal
nfection and/or fungal PJI.
.2. Surgical therapy
Table 2 summarizes the surgical and medical therapy for these
 patients. Two-stage exchange arthroplasty was performed for
ll 5 patients. After removal of all components and a thorough
ebridement, an articulating cement spacer made intraoperatively
ccording to Shen et al. [10] was implanted (Fig. 1A). Amphotericin
 and vancomycin loaded bone cement (100 mg  amphotericin B
ombined with 1 g vancomycin per batch of bone cement) was  used
n all patients. The mean interval between resection and reimplan-
ation was 6 months (range, 3 to 9 months). Bone cement used for
eimplantation was loaded with amphotericin B and vancomycin
100 mg  amphotericin B combined with 1 g vancomycin per 40 g
one cement) in all patients.: Surgery & Research 101 (2015) 151–156
2.3. Medical therapy
Systemic antifungal therapy was  administered to all patients.
After implant removal and bone cement spacer implantation,
patients were treated with parenteral ﬂuconazole (400 mg/day)
combined with parenteral cefuroxime and levoﬂoxacin for 2
weeks, followed by oral ﬂuconazole (400 mg/day), levoﬂoxacin and
rifampicin for 4 to 8 weeks until CRP and ESR values returned to nor-
mal. After reimplantation, antimicrobial therapy for all 5 patients
was consisted of parenteral ﬂuconazole (400 mg/day), cefuroxime
and levoﬂoxacin for 2 weeks. Culture of intraoperative specimen
during reimplantation yielded Staphylococcus auricularis in one
patient (case No. 4). Prolonged antimicrobial therapy consisted of
oral levoﬂoxacin and rifampicin for 4 more weeks was  prescribed
for this patient. The other 4 patients received no prolonged antimi-
crobial therapy.
2.4. Data collection
Data collected from the patient’s medical record and follow-up
record included: age, sex, primary or revision surgery, comor-
bidity, preoperative diagnosis, symptoms, global IKS score [11],
range of motion of the knee joint, interval between primary
surgery and onset of symptoms of infection, species isolated,
origin of culture samples (i.e. aspiration, intraoperative, other),
other microorganisms cultured, C-reactive protein (CRP, mg/L) and
erythrocyte sedimentation rate (ESR, mm/h) at presentation, radio-
graphic ﬁndings, local and systemic antimicrobial therapy, duration
of antimicrobial therapy, type of surgical treatment, time from
resection to reimplantation, and duration of follow-up.
3. Results
3.1. Clinical features
Four patients (80%) had signiﬁcant pain, swelling, warmth, red-
ness and sinus tract formation at presentation (Fig. 1B). The other
patient without draining sinus had slight pain, swelling and stiff-
ness of the knee, with an active range of motion (ROM) of only 10
degrees and a passive ROM of about 30 degrees (Table 1). At pre-
sentation, 1 patient had normal CRP and ESR, 1 patient had normal
CRP and elevated ESR, the other 3 patients had signiﬁcantly ele-
vated CRP and ESR. On plain X-ray ﬁlm, 1 patient (case No. 1) had
only slight radiolucent lines (RLLs) around the posterior condyle of
the femoral component and had no osteolytic lesions. The other 4
patients had signiﬁcant osteolysis beneath the tibial components
(Fig. 1C).
3.2. Microbiology
Cultures of preoperative aspirate specimens from all 5 patients
were positive for fungus. The pathogen organisms included Pichia
anomala (also named Candida pelliculosa)  in 1 patient, Candida
utilis in 1 patient and Candida parapsilosis in the other 3 patients,
which were consistent with the culture results of their intraop-
erative specimens (Table 1). Susceptibility tests were performed
in all cases. The causative organism was susceptible to ﬂucona-
zole, ketoconazole, voriconazole, itraconazole and amphotericin B
in all cases. No patient had a polymicrobial infection at the time of
diagnosis.3.3. Treatment outcome
We  did not observe mechanical complications between stages
such as spacer fractures or dislocations. The median duration of
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Table  1
Demographic and clinical characteristics of patients with fungal peri-prosthetic joint infection following primary total knee arthroplasty.
Case No. Age (year)/sex Comorbidities/risk
factors
Pathogen
organism
Symptoms Radiographic
ﬁndings
Time from
implantation to
diagnosis of PJI
(months)
CRP (mg/l) at
presentation
ESR (mm/h) at
presentation
1 67/F Leucopenia,
diabetes
mellitus
Candida
parapsilosis
Slight pain,
warmth,
swelling and
stiffness of the
knee
Radiolucency
at femoral side
5 22.4 39
2  56/F None Candida utilis Signiﬁcant
pain, swelling,
warmth,
redness and
sinus tract
formation
Osteolysis
beneath the
tibial tray
5 3.53 29
3  74/M Diabetes
mellitus
Candida
parapsilosis
Signiﬁcant
pain, swelling,
warmth,
redness and
sinus tract
formation
Radiolucency
at femoral side
and osteolysis
beneath the
tibial tray
10 5.22 41
4  68/M None Pichia anomala Signiﬁcant
pain, swelling,
warmth,
redness and
sinus tract
formation
Osteolysis
beneath the
tibial tray
8 48 38
5  71/F None Candida
parapsilosis
Signiﬁcant
pain, swelling,
warmth,
redness and
sinus tract
ion
Osteolysis
beneath the
tibial tray
9 34.6 54
C
f
t
a
d
g
o
T
6
a
i
e
p
4
r
o
s
a
a
i
a
p
o
c
a
a
o
t
o
dformat
RP: C-reactive protein; ESR: erythrocyte sedimentation rate; F: female; M: male.
ollow-up was 41.6 months (range, 24–65 months) after reimplan-
ation. At latest follow-up visit, no patient had recurrent infection
fter successful reimplantation. All patients performed activities of
aily living well and were satisﬁed with the revision TKA. The mean
lobal IKS score improved from 58.4 (range, 37 to 96 points) pre-
peratively to 152.4 (range, 136 to 169 points) at ﬁnal follow-up.
he average range of motion of the knee for ﬂexion improved from
3◦ (range, 10 to 110◦) preoperatively to 98◦ (range, 80 to 120◦)
t ﬁnal follow-up. There was no radiological evidence of loosen-
ng of the revised prosthesis in any patient (Fig. 1D). No adverse
vents related to antifungal or antibiotic therapy were noted in all
atients.
. Discussion
With the signiﬁcantly improved functional outcome and no
ecurrence of infection in our 5 cases of fungal PJI following TKA,
ur working hypothesis was conﬁrmed. Fungal PJI can be treated
uccessfully by our 2-stage reimplantation strategy. Antibiotic- and
ntifungal-loaded cement articulating spacers may  be an effective
djunct to therapy. Systemic antifungal therapy for at least 6 weeks
s crucial to a successful result in treating fungal PJI and prolonged
ntifungal therapy more than 2 weeks is not necessary after reim-
lantation.
The major limitation of the current study is the small number
f cases due to the rarity of fungal PJI. However, we treated all 5
ases with the same protocol including the use of antibiotic- and
ntifungal-loaded cement spacer and the combined use of rifampin
nd antibiotics with antifungal agent, which is different to those
f other studies and can provide new and valuable information to
he treatment of fungal PJI. We  did not evaluate the serum level
f ﬂuconazole, which is a limitation of our present study. But the
osage of ﬂuconazole we prescribed for our patients (400 mg/day)was relatively high, and this might possibly resulted in a serum level
of ﬂuconazole above the MIC  despite the inﬂuence of rifampicin.
There exist no established guidelines in the treatment of fungal
PJI. Although there is now a growing number of reports of success-
ful 2-stage reimplantation, there were still a large proportion of
patients (28.6%, 34/119) with fungal PJI who  underwent permanent
prosthesis removal and subsequently had poor functional outcome
[3]. This differs from the common practice of delayed reimplanta-
tion arthroplasty for total hip and knee PJIs due to other organisms.
Staged revision has the highest success rate (85%) in treating
fungal PJI [3], thus it should be the standard treatment for fungal
PJI. The ideal interval between implant removal and reimplantation
is unknown, because fungal PJIs are notoriously indolent and there
is no consistent test for successful eradication. A review of 79 two-
stage revision cases found a mean interval of 4.8 months, with a
range from 1 week to 1.5 years [3]. The mean interval in our case
series was 6 months (range, 3 to 9 months). We  recommend that
reimplantation should be performed only in the absence of clinical
signs of infectious symptoms, with CRP and ESR serum levels within
the normal range.
The introduction of antibiotic-loaded bone cement improved
the results of revision arthroplasty for bacterial sepsis, and it
is now considered the gold standard for the treatment of bac-
terial peri-prosthetic joint infections [12]. However, the efﬁcacy
of antifungal-loaded cement spacers in the treatment of fun-
gal peri-prosthetic joint infections is controversial. Theoretically,
amphotericin B seems to be an ideal agent to be mixed with bone
cement because of its heat stability, broad antimicrobial spectrum,
and availability in powder form. The placement of amphotericin
B-loaded cement spacers has been reported to successfully eradi-
cate fungal peri-prosthetic joint infections [6]. Bone cement loaded
with amphotericin B inhibits fungal growth in an agar diffusion
assay [13]. Another in vitro study of amphotericin B-loaded cement
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Table  2
Treatment characteristics of 5 patients with fungal peri-prosthetic joint infection following primary total knee arthroplasty.
Case No. Impregnation
of bone cement
during stage 1
revision
Medical
therapy after
stage 1 revision
Impregnation
of bone cement
during
reimplantation
Medical
therapy after
reimplantation
Duration of
follow-up
(months)
Outcome
(failure deﬁned
as recurrence
of infection)
1 V + A Parenteral ﬂuconazole
(400 mg/day) combined
with parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followed by oral
ﬂuconazole (400 mg/day),
levoﬂoxacin and rifampicin
(450 mg/day) for 8 weeks
V + A Parenteral ﬂuconazole
(400 mg/day)
combined with
parenteral cefuroxime
and levoﬂoxacin for 2
weeks
27 Cure
2  V + A Parenteral ﬂuconazole
(400 mg/day) combined
with parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followed by oral
ﬂuconazole (400 mg/day),
levoﬂoxacin and rifampicin
for 4 weeks
V + A Parenteral ﬂuconazole
(400 mg/day)
combined with
parenteral cefuroxime
and levoﬂoxacin for 2
weeks
24 Cure
3  V + A Parenteral ﬂuconazole
(400 mg/day) combined
with parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followd by oral
ﬂuconazole (400 mg/day),
levoﬂoxacin and rifampicin
for 6 weeks
V + A Parenteral ﬂuconazole
(400 mg/day)
combined with
parenteral cefuroxime
and levoﬂoxacin for 2
weeks
30 Cure
4  V + A Parenteral ﬂuconazole
(400 mg/day) combined
with parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followd by oral
ﬂuconazole (400 mg/day),
levoﬂoxacin and rifampicin
for 8 weeks
V + A Parenteral ﬂuconazole
(400 mg/day)
combined with
parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followed by oral
levoﬂoxacin and
rifampicin for 4 weeks
65 Cure
5  V + A Parenteral ﬂuconazole
(400 mg/day) combined
with parenteral cefuroxime
and levoﬂoxacin for 2
weeks, followed by oral
ﬂuconazole (400 mg/day),
levoﬂoxacin and rifampicin
V + A Parenteral ﬂuconazole
(400 mg/day)
combined with
parenteral cefuroxime
and levoﬂoxacin for 2
weeks
62 Cure
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 + A: 1 g of vancomycin and 100 mg  of amphotericin B per 40 g of bone cement.
as shown only poor elution characteristics for amphotericin B
14]. However, the elution characteristics of amphotericin B in vivo
ircumstances could be different. Deelstra et al. [15] reported clin-
cally detectable elution of amphotericin B from bone cement for
t least 72 hours, with the elution levels well above the MIC  lev-
ls determined for Candida albicans. We  consider local antifungal
elivery an important part in treating fungal PJI. According to litera-
ure, fungal joint infections have a high risk of subsequent bacterial
nfections [16], culture of intraoperative specimen during reim-
lantation yielded S. auricularis in one of our patients, and a lot of
atients have a combined fungal and bacterial PJI (33%) [3]. Thus,
e decided to impregnate the bone cement with vancomycin and
mphotericin B during cement spacer implantation and second
tage reimplantation in all patients. Addition of amphotericin B did
ot impair the mechanical properties of bone cement [14].
Antifungal therapy appears to be an important component in
he successful treatment of fungal PJI. There is evidence that oral
uconazole penetrates tissues well and has excellent bioavailabil-
ty [17]. It appears that ﬂuconazole is an ideal drug for fungal PJI.
 long period of oral antifungal treatment has been recognized as
eing an essential factor for the success of staged reimplantation
fter a fungal peri-prosthetic joint infection. However, the required
uration of treatment is unclear. The Infectious Diseases Society of
merica recommends treatment with ﬂuconazole or amphotericinB for at least 6 weeks after removal of the arthroplasty in most
patients with fungal PJI [9]. A review of the literatures shows that
duration (comparing 6 weeks and 3 months of antifungal treat-
ment) does not appear to inﬂuence outcome after reimplantation
[3]. We  agree with the opinion of most authors that a minimum
duration of antifungal treatment of 6 weeks is required. In the cur-
rent study, systemic administration of ﬂuconazole was given for 6
to 10 weeks after implant removal until serum CRP and ESR lev-
els had normalized. All these 5 patients received only 2 weeks of
antifungal therapy after reimplantation. Because antifungal agents
possess a good tissue penetration in infected wounds after systemic
administration, we believe that prolonged antifungal therapy is not
necessary after reimplantation. Because of the concern about the
subsequent or combined bacterial infections with fungal PJI, we
decided to use other antibiotics (rifampicin and levoﬂoxacin) in
combination with ﬂuconazole as our medical treatment regimen.
The use of rifampicin and levoﬂoxacin after implant removal in
spite of negative bacterial culture is speciﬁc to our center. Indeed
current recommendations do not support this systematic antibi-
otic adjunction to antifungal treatment without microbiological
argument [9]. There is a major concern about the pharmacokinetic
interaction between rifampicin and antifungal agent. A synergistic
effect between amphotericin B and rifampicin was demonstrated
against Candida species bioﬁlms [18]. Moreover, rifampicin showed
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Fig. 1. A 74-year-old male patient presented with signiﬁcant pain and swelling of the right knee 10 months after primary total knee arthroplasty. A. After removal of all
implants and a thorough debridement, a cement spacer impregnated with vancomycin and amphotericin B was implanted. B. Warmth, redness and a draining sinus were
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zoted  on physical examination. C. Preoperative X-ray showed signiﬁcant osteolysis 
fter  reimplantation.
igh in vitro activity against most staphylococcal strains iso-
ated from the PJIs tested [19]. Although rifampicin can induce
he metabolism of azole antifungals and reduce their serum lev-
ls [20], in Turker et al. study [21], four of ﬁve patients with
ryptococcosis who received itraconazole and rifampin responded
espite decreases in their serum itraconazole concentrations. In
nother study, rifampicin did not change the clinical outcome
f ﬂuconazole in treating patients with AIDS-related cryptococ-
al meningitis despite decreased serum ﬂuconazole concentrations
22]. We  were fully aware of the potential side effects and ﬂucona-
ole and rifampicin interactions, but we tried our best to monitorth the tibial components. D. Anteroposterior and lateral view X-ray ﬁlm 18 months
the side effects of these drugs closely. It turned out that all our 5
patients tolerated our medical therapy regimen well.
5. Conclusions
Fungal peri-prosthetic joint infection following total knee
arthroplasty can be successfully treated by removal of the pros-
thesis, thorough debridement, and effective antifungal therapy.
Antibiotic- and antifungal-loaded cement spacer implanted dur-
ing interval period between stages may  be an effective adjunct to
therapy. Systemic antifungal therapy for at least 6 weeks is crucial
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o a successful result in treating fungal PJI and prolonged antifungal
herapy more than 2 weeks is not necessary after reimplantation.
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